400 related articles for article (PubMed ID: 19211798)
21. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
22. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
Angelini DF; Serafini B; Piras E; Severa M; Coccia EM; Rosicarelli B; Ruggieri S; Gasperini C; Buttari F; Centonze D; Mechelli R; Salvetti M; Borsellino G; Aloisi F; Battistini L
PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979
[TBL] [Abstract][Full Text] [Related]
23. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
24. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation.
Smith C; Wakisaka N; Crough T; Peet J; Yoshizaki T; Beagley L; Khanna R
Blood; 2009 Jun; 113(24):6148-52. PubMed ID: 19372256
[TBL] [Abstract][Full Text] [Related]
25. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
26. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana.
Ayee R; Ofori MEO; Tagoe EA; Languon S; Searyoh K; Armooh L; Bilson-Amoah E; Baidoo K; Kitcher E; Wright E; Quaye O
Viruses; 2020 Jul; 12(7):. PubMed ID: 32708700
[TBL] [Abstract][Full Text] [Related]
27. Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.
Tschochner M; Leary S; Cooper D; Strautins K; Chopra A; Clark H; Choo L; Dunn D; James I; Carroll WM; Kermode AG; Nolan D
PLoS One; 2016; 11(2):e0147567. PubMed ID: 26849221
[TBL] [Abstract][Full Text] [Related]
28. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
[TBL] [Abstract][Full Text] [Related]
29. EBV-Specific Immune Response: Early Research and Personal Reminiscences.
Moss DJ; Lutzky VP
Curr Top Microbiol Immunol; 2015; 390(Pt 1):23-42. PubMed ID: 26424642
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
32. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
33. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
Pender MP; Csurhes PA; Lenarczyk A; Pfluger CM; Burrows SR
J Neurol Neurosurg Psychiatry; 2009 May; 80(5):498-505. PubMed ID: 19015225
[TBL] [Abstract][Full Text] [Related]
34. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
35. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
36. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
37. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
38. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.
Lin JC; Chen KY; Wang WY; Jan JS; Liang WM; Tsai CS; Wei YH
J Clin Oncol; 2001 May; 19(10):2607-15. PubMed ID: 11352952
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis.
Masuoka S; Kusunoki N; Takamatsu R; Takahashi H; Tsuchiya K; Kawai S; Nanki T
PLoS One; 2018; 13(12):e0208957. PubMed ID: 30533036
[TBL] [Abstract][Full Text] [Related]
40. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]